COMPUMEDICS LIMITED — Regulatory Filings 2009

Apr 21, 2009

ASX / MEDIA RELEASE

==> picture [76 x 80] intentionally omitted <==

Compumedics Limited benefits as US market chooses quality

Melbourne Australia, Wednesday, 22 April, 2009

Leading medical devices company, Compumedics Limited (ASX:CMP) today announced it has won several large sleep-diagnostic equipment sales in its key US market in the first months of calendar 2009. The orders have been around $285k (USD200k) each.

The hospitals and medical institutions which placed these orders demand quality, technical innovation and reliability and, as such, Compumedics is a natural vendor of choice. Importantly, some of these deals displaced equipment provided initially by existing competitors, which confirms Compumedics’ technological lead in its range of sleep-diagnostic equipment.

Compumedics’ range of laboratory-based, ambulatory and home-based sleep-diagnostic equipment is extremely well suited and flexible in configuration to meet the current and future needs of large, premium and demanding sleep-diagnostic centers.

This new business increments that detailed in our recent announcement regarding the achievement of a major milestone for our newly established Germany based sleepdiagnostic equipment business after winning a $400k (€220k) order for equipping a 12bed sleep-diagnostic center in a prestigious German hospital.

The recent success in the US with larger orders and the winning of the German contract confirms Compumedics’ strategic advancement and progress in developing its key US and European markets and the Company’s continued focus on key global markets, despite the economic conditions that may exist from time-to-time.

Compumedics recently announced for the six-month period to 31 December 2008, a $2.5 m NPAT, the highest level of operating cash for any six-month period in more than 4 years and the fifth consecutive, positive six-monthly operating cash report to market. Over the past three years, the Company’s earnings have increased by AUD5.0 m, the bank debt reduced from AUD6.5 m to AUD1.9 m, manufacturing gross margins have improved by 7%, and costs have reduced by AUD5.0 m. The Company has also consistently generated positive cash over this period and is now well positioned for accelerated global expansion such as reported here.

Compumedics Limited (ASX:CMP)

Released on 22 April, 2009 Page 1 of 2

For Further information:

Mr David Burton Executive Chairman, CEO Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399

Mr David Lawson Chief Financial Officer Phone: + 61 3 8420 7300 Fax: +61 3 8420 7399

Investor Relations & Media Enquires:

Mr Rod North Executive Director Bourse Communications Pty Ltd Phone: +61 3 9510 8309 Mobile: +61 (0) 408 670 706

About Compumedics

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific’s first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world’s largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002 , Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In 2004 , Compumedics acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006 , Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. In 2007 , Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from $9 million (1999) to $39 million (2008). www.compumedics.com

Compumedics Limited (ASX:CMP)

Released on 22 April, 2009 Page 2 of 2